Clinical Features and Prognosis of 60 Cases of HIV-negative Plasmablastic Lymphomas Patients

XU Wenjing; WANG Pei; MA Yueshi; GAO Liping

doi:10.3971/j.issn.1000-8578.2021.20.0878

Cancer Research on Prevention and Treatment > 2021 > 48(4): 375-380. > DOI: 10.3971/j.issn.1000-8578.2021.20.0878

XU Wenjing, WANG Pei, MA Yueshi, GAO Liping. Clinical Features and Prognosis of 60 Cases of HIV-negative Plasmablastic Lymphomas Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 375-380. DOI: 10.3971/j.issn.1000-8578.2021.20.0878

Citation:

PDF (3053 KB)

Clinical Features and Prognosis of 60 Cases of HIV-negative Plasmablastic Lymphomas Patients

Department of Oncology, Chongqing Traditional Chinese Medicine Hospital, Chongqing 400021, China

More Information

Corresponding author:
GAO Liping, E-mail: 13310240092@163.com
Received Date: July 21, 2020
Revised Date: December 01, 2020
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the clinical features and prognosis of HIV-negative plasmablastic lymphoma (PBL) patients.
Methods
We collected HIV-negative PBL cases reported in our hospital and other literatures from online databases from January 1, 1997 to March 30, 2020. The data of clinical features, molecular pathology, treatment and prognosis were summarized and analyzed.
Results
We included 60 PBL patients, average age was 53.06±14.36 years, and most of them had relatively high Ann Arbor stage and Ki-67 expression. The average OS was 13.48±13.21 m. Kaplan-Meier curve revealed Ann Arbor stage, IPI index (3-5), B symptoms and CR in initial treatment were significantly related with patients' survival. Cox regression analysis indicated that the Ann Arbor stage and IPI index were the independent prognostic factors for patients' survival. Conclusion HIV-negative PBL mostly occurs in the middle-age and elderly patients, with advanced diagnosis stage and rapid tumor proliferation.
Combination
chemotherapy is the main treatment, while the therapeutic response and OS might be heterogeneous, the prognosis of most patients would be poor. The stage and IPI index are significantly related to the prognosis.
- Lymphoma,
- Clinical features,
- Treatment,
- Prognosis

FullText(HTML)

References (21)

References

[1]	Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569
[2]	Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma[J]. Blood, 2015, 125(15): 2323-2330. doi: 10.1182/blood-2014-10-567479
[3]	Reardon S. Infections reveal inequality between the sexes[J]. Nature, 2016, 54(7608): 447.
[4]	Liu M, Liu B, Liu B, et al. Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases[J]. Oncol Rep, 2015, 33(4): 1615-1620. doi: 10.3892/or.2015.3808
[5]	蓝三春, 谢婧, 朱搏宇, 等. 乙型肝炎病毒相关浆母细胞淋巴瘤1例并文献复习[J]. 军事医学, 2018, 42(1): 77-78, 80. https://www.cnki.com.cn/Article/CJFDTOTAL-JSYX201801031.htm Lan SC, Xie J, Zhu BY, et al. A case of hepatitis B virus-related plasmablastic lymphoma and literature review[J]. Jun Shi Yi Xue, 2018, 42(1): 77-78, 80. https://www.cnki.com.cn/Article/CJFDTOTAL-JSYX201801031.htm
[6]	Sarode SC, Sarode GS, Patil A. Plasmablastic lymphoma of the oral cavity: a review[J]. Oral Oncol, 2010, 46(3): 146-153. doi: 10.1016/j.oraloncology.2009.12.009
[7]	Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives[J]. Blood Lymphat Cancer, 2018, 8: 63-70. http://www.researchgate.net/publication/328072487_Plasmablastic_lymphoma_current_perspectives/download
[8]	Bhatt R, Desai DS. Plasmablastic Lymphoma[M/OL]. StatPearls Publishing[2020-8-24]. https://www.ncbi.nlm.nih.gov/books/NBK532975/
[9]	Castillo JJ, Winer ES, Stachurski D, et al. HIV-negative plasmablastic lymphoma: not in the mouth[J]. Clin Lymphoma Myeloma Leuk, 2011, 11(2): 185-189. doi: 10.1016/j.clml.2011.03.008
[10]	Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma[J]. Leuk Lymphoma, 2010, 51(11): 2047-2053. doi: 10.3109/10428194.2010.516040
[11]	Akce M, Chang E, Haeri M, et al. Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma[J]. Case Rep Hematol, 2016, 2016: 3598547. http://www.ncbi.nlm.nih.gov/pubmed/27957358
[12]	范舟, 李基炜, 易平勇, 等. 5例浆母细胞淋巴瘤临床病例分析和文献回顾[J]. 肿瘤药学, 2018, 8(1): 124-128. doi: 10.3969/j.issn.2095-1264.2018.01.29 Fan Z, Li JW, Yi PY, et al. Case Report on 5 Plasmablastic Lymphoma Patients and Literature Review by Retrospective Analysis[J]. Zhong Liu Yao Xue, 2018, 8(1): 124-128. doi: 10.3969/j.issn.2095-1264.2018.01.29
[13]	Yan M, Dong Z, Zhao F, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab[J]. Eur J Haematol, 2014, 93(1): 77-80. doi: 10.1111/ejh.12286
[14]	Holderness BM, Malhotra S, Levy NB, et al. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia[J]. J Clin Oncol, 2013, 31(12): e197-199. doi: 10.1200/JCO.2012.46.9593
[15]	Pretscher D, Kalisch A, Wilhelm M, et al. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy[J]. Ann Hematol, 2017, 96(6): 967-970. doi: 10.1007/s00277-016-2904-7
[16]	Mine S, Hishima T, Suganuma A, et al. Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets[J]. Sci Rep, 2017, 7(1): 10188. doi: 10.1038/s41598-017-10684-5
[17]	Koenig G, Stevens TM, Peker D. Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy[J]. Histopathology, 2015, 67(6): 930-932. doi: 10.1111/his.12718
[18]	Yanamandra U, Sahu KK, Jain N, et al. Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings[J]. Ann Hematol, 2016, 95(10): 1715-1717. doi: 10.1007/s00277-016-2732-9
[19]	Laurent C, Fabiani B, Do C, et al. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients[J]. Haematologica, 2016, 101(8): 976-984. doi: 10.3324/haematol.2016.141978
[20]	Cattaneo C, Finel H, McQuaker G, et al. Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience[J]. Biol Blood Marrow Transplant, 2015, 21(6): 1146-1147. doi: 10.1016/j.bbmt.2015.03.008
[21]	Elyamany G, Al Mussaed E, Alzahrani AM. Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions[J]. Adv Hematol, 2015, 2015: 315289. http://www.ncbi.nlm.nih.gov/pubmed/27110244

[1]	DAI Nan, ZHAO Xiaolong, DAI Xiaoyan, LI Mengxia. Effect of Exosomal APE1 on Sensitivity of NSCLC A549 Cells to Cisplatin[J]. Cancer Research on Prevention and Treatment, 2020, 47(7): 492-497. DOI: 10.3971/j.issn.1000-8578.2020.19.1609
[2]	HUANG Zejian, FANG Chang, YU Baodan, CHENG Qing, LYU Ping. 3E10 Targeting CD24 Enhances Chemotherapy Sensitivity of Hepatocellular Carcinoma HuH-7 Cells[J]. Cancer Research on Prevention and Treatment, 2018, 45(8): 540-544. DOI: 10.3971/j.issn.1000-8578.2018.17.1484
[3]	CAI Rui, CHEN Qiuqiu, JIANG Wei. 5-azacytidine Increases Radiation Sensitivity of Nasopharyngeal Carcinoma Cell Line C666-1[J]. Cancer Research on Prevention and Treatment, 2017, 44(2): 94-97. DOI: 10.3971/j.issn.1000-8578.2017.02.003
[4]	ZHANG Juping, SHI Yehui, JIA Yongsheng, ZHOU Liyan, TONG Zhongsheng. GDF11 is Involved in Human Hepatic Carcinoma Cells SMMC-7721 Proliferation and Sensitivity to DDP[J]. Cancer Research on Prevention and Treatment, 2016, 43(6): 459-462. DOI: 10.3971/j.issn.1000-8578.2016.06.005
[5]	LI Wei, PENG Junqin, LI Jiansheng, TANG Rijie. MR Apparent Diffusion Coefficient Predicts Sensitivity of Nasopharyngeal Carcinoma to Radiotherapy and Related Factors[J]. Cancer Research on Prevention and Treatment, 2015, 42(12): 1221-1226. DOI: 10.3971/j.issn.1000-8578.2015.12.011
[6]	HU Lili, YIN Yanjun, ZHONG Wenjuan, QIU Feng. miR-200c Enhances Sensitivity of Lung Cancer Cell A549 to Paclitaxel and Gefitinib and Related Mechanism[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 760-764. DOI: 10.3971/j.issn.1000-8578.2015.08.003
[7]	CAO Xinmei, ZHANG Daiquan, XIA Jiyi, WANG Xu, GAO Yan, XIONG Wei. Effects of HER2 shRNA on Chemotherapy Sensitivity of Mouse Lewis Cells[J]. Cancer Research on Prevention and Treatment, 2014, 41(05): 366-368. DOI: 10.3971/j.issn.1000-8578.2014.05.004
[8]	Yang Qingshan, Liu Yuanyuan, Jiang Lipeng. Effect of Expression Vector of Human BAG-1 Gene on Radio-sensitivity of Lung Adenocarcinoma Cells[J]. Cancer Research on Prevention and Treatment, 2012, 39(02): 127-129. DOI: 10.3971/j.issn.1000-8578.2012.02.002
[9]	FANG Chuan, TAN Yan-li, WANG Jia-liang, SHI Yan-fang, SHAN Xiao-song, LI Wei. Primary Culture and Drug Sensitivity of Human Glioma Cells[J]. Cancer Research on Prevention and Treatment, 2010, 37(12): 1380-1382. DOI: 10.3971/j.issn.1000-8578.2010.12.012
[10]	ZHANG Wei, GU Min. Geldanamycin Sensitizes Human Breast Cancer Cells to Adriamycin both in vitro and in vivo[J]. Cancer Research on Prevention and Treatment, 2010, 37(10): 1109-1112. DOI: 10.3971/j.issn.1000-8578.2010.10.004

Cited By

Cited by

Periodical cited type(9)

1.	成俊，徐雪峰，李伟. D-CBCT在肺癌容积旋转调强计划精准治疗中的临床应用. 中国CT和MRI杂志. 2024(04): 35-37 .
2.	蒋浩，曹新超，吴桐，郭志斌. 低剂量CT联合外周血循环肿瘤细胞在肺癌早期诊断中的价值研究. 中国CT和MRI杂志. 2024(06): 57-60 .
3.	王晶，翟成凯. 肿瘤自身抗体及CT人工智能在NSCLC早期诊断中的应用研究进展. 解放军医学杂志. 2024(07): 848-854 .
4.	李雪娇. 多排螺旋CT低剂量胸部扫描在肺癌早期筛查中的应用价值分析. 医药前沿. 2024(15): 79-81 .
5.	易梅玲，易芳玲. 双层探测器光谱CT智能剂量调控技术在低剂量胸部体检中的应用价值. 中国医疗器械信息. 2024(22): 8-10+81 .
6.	杏子，彭源. 低剂量CT在肺癌筛查中的价值. 中国防痨杂志. 2024(S2): 234-236 .
7.	陈蔚，蒋伟. 低剂量螺旋CT扫描用于肺癌筛查及鉴别的效果评估. 深圳中西医结合杂志. 2023(01): 71-73 .
8.	慕珂珂，肖凌云，董炎红. 早期肺癌患者血清和胸腔积液中CYFRA211、NSE及SCC水平变化及意义. 中国实用医刊. 2023(09): 34-37 .
9.	陈彪. 低剂量螺旋CT联合血清肿瘤标志物在肺癌诊断中的临床应用价值. 影像研究与医学应用. 2023(22): 24-26 .

Other cited types(1)

Get Citation

PDF

XML

Article views (1505) PDF downloads (410) Cited by(10)

Turn off MathJax

Article Contents

Abstract

References

Clinical Features and Prognosis of 60 Cases of HIV-negative Plasmablastic Lymphomas Patients